{"id":2251,"date":"2023-07-18T20:00:24","date_gmt":"2023-07-19T00:00:24","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/towards-the-development-of-a-new-class-of-anti-gpcr-antibodies-for-the-treatment-of-aggressive-cancers\/"},"modified":"2024-09-25T16:25:38","modified_gmt":"2024-09-25T20:25:38","slug":"towards-the-development-of-a-new-class-of-anti-gpcr-antibodies-for-the-treatment-of-aggressive-cancers","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/towards-the-development-of-a-new-class-of-anti-gpcr-antibodies-for-the-treatment-of-aggressive-cancers\/","title":{"rendered":"Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers"},"content":{"rendered":"\n

Challenge:<\/strong> G protein-coupled receptors (GPCRs) represent attractive biomarkers and therapeutic target classes in cancer research because their aberrant expression and activity are closely correlated with different stages of tumour initiation and progression. The development of small molecule anticancer drugs targeting GPCRs has so far proven to be quite challenging. Thus, there remains a need to identify new approaches to treating cancer with GPCR-targeted drugs.<\/p>\n\n\n\n

Solution:<\/strong> One\u00a0approach\u00a0investigated in this project was to develop next\u00a0generation therapeutic\u00a0antibodies capable of modulating GPCR signaling.\u00a0Researchers\u00a0from the University of\u00a0Sherbrooke\u00a0are\u00a0combining their expertise in GPCR signaling, drug discovery and cancer biology,\u00a0with\u00a0that of scientists from\u00a0Immune\u00a0Biosolutions\u00a0(IBio), a Qu\u00e9bec biotech specializing in the production of chicken antibodies,\u00a0to\u00a0generate novel\u00a0GPCR-directed antibodies, targeting malignant\u00a0human\u00a0cancers. Candidate\u00a0GPCR\u00a0targets for cancer therapy include\u00a0the\u00a0kinin B1 receptor\u00a0(B1R), mostly involved in\u00a0triple-negative breast cancer and prostate cancer,\u00a0and the\u00a0neurotensin 1 receptor\u00a0(NTS1R), mostly involved in\u00a0non-small cell lung cancer and colorectal cancer. IBio\u2019s platform\u00a0Nebula was considerably improved and\u00a0enabled the development of two antibodies against B1R that showed\u00a0diagnostic, but not therapeutic, potential, as well as the development of one antibody against NTS1R that showed antitumoral activities\u00a0in vitro<\/em>\u00a0first and then\u00a0in vivo<\/em>, after optimization,\u00a0in a mouse model.<\/p>\n\n\n\n

Achievements\/Impact:<\/strong>\u00a0This\u00a0project\u00a0enabled\u00a0the\u00a0optimization\u00a0of the platform as a\u00a0bona fide<\/em>\u00a0drug discovery strategy, now\u00a0available\u00a0from\u00a0IBio\u00a0for\u00a0other projects, as well as\u00a0the development of\u00a0GPCR-targeted therapeutics.\u00a0IBio\u2019s\u00a0optimized platform was\u00a0actually awarded\u00a0a large funding for the discovery of SARS-CoV-2 \u2013 specific antibodies\u00a0at the end of the CQDM project, which are now evaluated in a Phase I trial.\u00a0The optimization of antibodies able to detect B1R-related cancers is promising for early cancer detection, while the optimization of antibodies able to block NTS1R-related cancers in preliminary studies is promising in the fight against these aggressive cancers.<\/p>\n\n\n\n

Principal Investigator:<\/strong>
Fernand Gobeil Jr
<\/strong>Universit\u00e9 de Sherbrooke<\/td><\/tr>
Co-investigators<\/strong>
Philippe Sarret<\/strong>
Universit\u00e9 de Sherbrooke
Fernand-Pierre Gendron<\/strong>
Universit\u00e9 de Sherbrooke
Simon Gaudreau<\/strong>
Immune Biosolutions<\/td><\/tr>
Completed <\/strong><\/strong><\/strong>Project<\/strong><\/td><\/tr>
$887,685 \/ 2 years<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/td><\/tr>
Supported by CQDM through:<\/strong>
– MEI<\/td><\/tr>
And by co-funding partners:<\/strong>
– Immune Biosolutions
– Soci\u00e9t\u00e9 de recherche sur le cancer
– Transfertech
– Mitacs
– Facult\u00e9 de m\u00e9decine et sciences de la sant\u00e9
– Centre de recherche CHUS<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

Challenge: G protein-coupled receptors (GPCRs) represent attractive biomarkers and therapeutic target classes in cancer research because their aberrant expression and activity are closely correlated with different stages of tumour initiation and progression. The development of small molecule anticancer drugs targeting GPCRs has so far proven to be quite challenging. Thus, there remains a need to…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2251","post","type-post","status-publish","format-standard","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2251"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2251\/revisions"}],"predecessor-version":[{"id":4787,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2251\/revisions\/4787"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}